Profile data is unavailable for this security.
About the company
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
- Revenue in USD (TTM)0.00
- Net income in USD-81.75m
- Incorporated2018
- Employees75.00
- LocationAcrivon Therapeutics Inc480 Arsenal Way, Suite 100WATERTOWN 02472United StatesUSA
- Phone+1 (617) 207-8979
- Fax+1 (302) 636-5454
- Websitehttps://acrivon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plus Therapeutics Inc (USA) | 5.26m | -20.58m | 47.90m | 21.00 | -- | 6.77 | -- | 9.11 | -1.71 | -1.71 | 0.062 | 0.0384 | 0.41 | -- | -- | 250,381.00 | -160.45 | -80.94 | -- | -211.40 | -- | -- | -391.33 | -605.55 | -- | -2.19 | 0.00 | -- | 18.54 | -3.61 | 2.54 | -- | 59.47 | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.35m | 48.56m | 2.00 | -- | -- | -- | -- | -0.0396 | -0.0396 | 0.00 | -0.0817 | 0.00 | -- | -- | 0.00 | -904.16 | -- | -- | -- | -- | -- | -- | -- | -- | -7.46 | -- | -- | -- | -- | -19.61 | -- | -- | -- |
| CervoMed Inc | 6.16m | -25.58m | 49.13m | 15.00 | -- | 1.89 | -- | 7.98 | -2.87 | -2.87 | 0.6919 | 2.81 | 0.155 | -- | 7.58 | 410,652.00 | -64.37 | -54.89 | -71.42 | -60.99 | -- | -- | -415.36 | -428.45 | -- | -- | 0.00 | -- | 36.29 | -- | -650.08 | -- | -- | -- |
| Impact Biomedical Inc | 25.00k | -44.19m | 49.35m | 2.00 | -- | -- | -- | 1,973.99 | -3.76 | -3.76 | 0.0021 | -0.9691 | 0.0008 | -- | 3.33 | 12,500.00 | -136.32 | -18.99 | -260.12 | -26.29 | 52.00 | -- | -176,952.00 | -78,189.58 | 0.0182 | -0.2682 | 1.63 | -- | -- | -- | -469.83 | -- | -- | -- |
| Liminatus Pharma Inc | 0.00 | -2.27m | 49.80m | -- | -- | -- | -- | -- | -0.0872 | -0.0872 | 0.00 | -0.0608 | 0.00 | -- | -- | -- | -77.46 | -- | -- | -- | -- | -- | -- | -- | -- | -12.30 | -- | -- | -- | -- | 28.85 | -- | -- | -- |
| Mira Pharmaceuticals Inc | 0.00 | -28.42m | 50.25m | -- | -- | 6.28 | -- | -- | -1.52 | -1.52 | 0.00 | 0.1911 | 0.00 | -- | -- | -- | -115.28 | -- | -123.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.46 | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -12.36m | 51.49m | 23.00 | -- | -- | -- | -- | -3.03 | -3.03 | 0.00 | -2.94 | 0.00 | -- | -- | 0.00 | -110.62 | -144.86 | -1,640.97 | -870.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 51.98 | -- | -- | -- |
| Q32 Bio Inc | 0.00 | -42.10m | 52.17m | 26.00 | -- | -- | -- | -- | -3.45 | -3.45 | 0.00 | -1.50 | 0.00 | -- | -- | 0.00 | -51.87 | -36.08 | -61.53 | -39.62 | -- | -- | -- | -870.34 | -- | -- | -- | -- | -100.00 | -- | 57.74 | -- | -67.85 | -- |
| Instil Bio Inc | 0.00 | -75.08m | 52.63m | 14.00 | -- | 0.437 | -- | -- | -11.39 | -11.39 | 0.00 | 17.76 | 0.00 | -- | -- | 0.00 | -31.00 | -34.59 | -32.06 | -36.59 | -- | -- | -- | -469,515.20 | -- | -19.23 | 0.4127 | -- | -- | -- | 52.50 | -- | 116.55 | -- |
| Acrivon Therapeutics Inc | 0.00 | -81.75m | 52.70m | 75.00 | -- | 0.4097 | -- | -- | -2.13 | -2.13 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -45.42 | -- | -49.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.40 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 242.00k | -38.06m | 53.67m | 2.00 | -- | -- | -- | 221.76 | -2.32 | -2.32 | 0.0141 | -0.9304 | 0.0249 | -- | -- | -- | -391.21 | -210.73 | -- | -603.16 | 59.92 | -- | -15,727.69 | -- | -- | -- | -- | -- | -- | -- | 16.69 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -31.42m | 55.31m | 18.00 | -- | -- | -- | -- | -0.2138 | -0.2138 | 0.00 | -0.0396 | 0.00 | -- | -- | 0.00 | -706.86 | -- | -- | -- | -- | -- | -- | -- | -- | -231.10 | -- | -- | -- | -- | 83.01 | -- | -- | -- |
| PMV Pharmaceuticals Inc | 0.00 | -82.71m | 55.34m | 63.00 | -- | 0.4555 | -- | -- | -1.58 | -1.58 | 0.00 | 2.28 | 0.00 | -- | -- | 0.00 | -46.29 | -21.46 | -49.90 | -22.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 14.87 | -- | 43.14 | -- |
| Grace Therapeutics, Inc | 0.00 | -7.82m | 55.71m | 32.00 | -- | 0.8097 | -- | -- | -0.5851 | -0.5851 | 0.00 | 4.45 | 0.00 | -- | -- | -- | -11.85 | -24.13 | -12.22 | -25.07 | -- | -- | -- | -48,136.22 | -- | -- | 0.00 | -- | -- | -- | 25.56 | -- | -- | -- |
| Cingulate Inc | 0.00 | -22.06m | 56.52m | 13.00 | -- | 13.25 | -- | -- | -5.35 | -5.35 | 0.00 | 0.5811 | 0.00 | -- | -- | 0.00 | -183.12 | -157.80 | -264.65 | -303.36 | -- | -- | -- | -- | -- | -19.54 | 0.4783 | -- | -- | -- | 33.95 | -- | -26.92 | -- |
Data as of Feb 06 2026. Currency figures normalised to Acrivon Therapeutics Inc's reporting currency: US Dollar USD
42.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Sep 2025 | 8.34m | 26.43% |
| Citadel Advisors LLCas of 14 Nov 2025 | 1.54m | 4.89% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 888.13k | 2.82% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 623.40k | 1.98% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 586.88k | 1.86% |
| UBS Securities LLCas of 31 Dec 2025 | 348.54k | 1.11% |
| Two Sigma Investments LPas of 30 Sep 2025 | 319.21k | 1.01% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 300.92k | 0.95% |
| Jane Street Capital LLCas of 30 Sep 2025 | 289.25k | 0.92% |
| Geode Capital Management LLCas of 30 Sep 2025 | 192.03k | 0.61% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
